Key Points
- Insider sale: Mark Schoenberg sold 7,373 shares of UroGen (NASDAQ:URGN) on Feb. 3 at an average price of $19.69 for $145,174, reducing his stake by 4.84% to 144,985 shares (≈$2.85M), according to the SEC filing.
- Company/market context: UroGen is a clinical‑stage biopharma (lead product Jelmyto) with a market cap of about $969M and a 52‑week range of $3.42–$30; MarketBeat shows a consensus rating of “Moderate Buy” with a $33 target after recent quarterly EPS of -$0.69 (beat) and revenue of $27.5M (below estimates).
Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the sale, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Mark Schoenberg also recently made the following trade(s):
- On Wednesday, November 19th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00.
Urogen Pharma Stock Performance
Shares of NASDAQ:URGN opened at $20.71 on Thursday. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The firm has a market cap of $969.44 million, a PE ratio of -5.99 and a beta of 1.32. The firm's fifty day moving average is $22.29 and its 200-day moving average is $20.60.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.03. The company had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. Sell-side analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.
Wall Street Analyst Weigh In
URGN has been the subject of a number of analyst reports. D. Boral Capital reissued a "buy" rating and set a $33.00 target price on shares of Urogen Pharma in a research note on Friday, January 23rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Wall Street Zen upgraded Urogen Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, November 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Urogen Pharma in a research note on Monday, October 27th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Urogen Pharma has a consensus rating of "Moderate Buy" and a consensus target price of $33.00.
Get Our Latest Stock Report on Urogen Pharma
Institutional Investors Weigh In On Urogen Pharma
Several hedge funds and other institutional investors have recently modified their holdings of URGN. AQR Capital Management LLC raised its holdings in Urogen Pharma by 347.5% during the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock worth $1,262,000 after buying an additional 88,577 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after buying an additional 1,653 shares in the last quarter. Jane Street Group LLC raised its position in Urogen Pharma by 94.3% in the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock valued at $566,000 after buying an additional 24,839 shares during the last quarter. Truist Financial Corp bought a new position in Urogen Pharma during the 2nd quarter valued at $423,000. Finally, Bender Robert & Associates purchased a new position in Urogen Pharma during the 2nd quarter worth $475,000. Institutional investors own 91.29% of the company's stock.
Urogen Pharma Company Profile
(
Get Free Report)
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
